# Phase 2b Study in NASH to Assess IVA337

> **NCT03008070** · PHASE2 · COMPLETED · sponsor: **Inventiva Pharma** · enrollment: 247 (actual)

## Conditions studied

- Non-Alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** IVA337
- **DRUG:** IVA337
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03008070
- **Lead sponsor:** Inventiva Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-07
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-03-16
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03008070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03008070, "Phase 2b Study in NASH to Assess IVA337". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03008070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*